AFMD
$3.26
Affimed N.V.
($.05)
(1.51%)
AFMD
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.12)
Revenue:  $6.34 Mil
Tuesday
Nov 10
6:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when AFMD reports earnings?
Beat
Meet
Miss

Where is AFMD's stock price going from here?
Up
Flat
Down
Stock chart of AFMD
Analysts
Summary of analysts' recommendations for AFMD
Score
Grade
Pivots
Resistance
$3.52
$3.44
$3.35

$3.28

Support
$3.18
$3.11
$3.02
Tweet
Growth
Description
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.